Floatz logo

Niraparib

Cholangiocarcinoma

Peking University Cancer Hospital & InstituteSmall moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
73/ 100

Competitive context

93 Active assets in the Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 3BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3B
Docetaxel
Merck Sharp & Dohme LLC
Phase 2B
ETOMIDATE
Cheju Halla General Hospital
Phase 4B

View all 50 →

Same molecule, other indications

Niraparib is also rated in:

breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
ovarian neoplasmDormant
BB
Indicative ·
66 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →